Spinal Muscular atrophy carrier testing and newborn screening: Difference between revisions

Jump to navigation Jump to search
No edit summary
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
 
Line 3: Line 3:
{{CMG}}
{{CMG}}
__NOTOC__
__NOTOC__
{{Editor Help}}
 




Line 32: Line 32:
* [http://www.jtsma.org.uk Jennifer Trust for Spinal Muscular Atrophy] - A national charity in the UK dedicated both to supporting people affected by SMA, and investing in essential research into causes, treatments and eventually a cure for the condition
* [http://www.jtsma.org.uk Jennifer Trust for Spinal Muscular Atrophy] - A national charity in the UK dedicated both to supporting people affected by SMA, and investing in essential research into causes, treatments and eventually a cure for the condition
{{Diseases of the nervous system}}
{{Diseases of the nervous system}}
{{SIB}}
 


[[Category:Motor neuron disease]]
[[Category:Motor neuron disease]]

Latest revision as of 16:12, 20 August 2012

Spinal Muscular Atrophy Microchapters

Home

Patient Info

Overview

Epidemiology and Demographics

Risk Factors

Screening

Other forms

Molecular Biology

Genetics

Types

Diagnosis

Diagnosis

Full Differential Diagnosis

Symptom

Physical Examination

Electrolyte & Biomarker Studies

Electrocardiogram

Chest X Ray

MRI and CT

Echocardiography or Ultrasound

Other Imaging Findings

Pathology

Other Diagnostic Studies

Treatment

Outcome measures

Therapeutics development

Indications For Surgery

Research

Pre-Operative Assessment

Post-Operative Assessment

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Spinal Muscular atrophy carrier testing and newborn screening Resources

Most recent articles on Spinal Muscular atrophy carrier testing and newborn screening

Most cited articles on Spinal Muscular atrophy carrier testing and newborn screening

Review articles on Spinal Muscular atrophy carrier testing and newborn screening

Review articles on Spinal Muscular atrophy carrier testing and newborn screening

CME Programs on Spinal Muscular atrophy carrier testing and newborn screening

Powerpoint slides on Spinal Muscular atrophy carrier testing and newborn screening

Images of Spinal Muscular atrophy carrier testing and newborn screening

Ongoing Trials on Spinal Muscular atrophy carrier testing and newborn screening at Clinical Trials.gov

US National Guidelines Clearinghouse on Spinal Muscular atrophy carrier testing and newborn screening

NICE Guidance on Spinal Muscular atrophy carrier testing and newborn screening

FDA on Spinal Muscular atrophy carrier testing and newborn screening

CDC on Spinal Muscular atrophy carrier testing and newborn screening

Spinal Muscular atrophy carrier testing and newborn screening in the news

Blogs on Spinal Muscular atrophy carrier testing and newborn screening

Directions to Hospitals Treating Spinal Muscular atrophy carrier testing and newborn screening

Risk calculators and risk factors for Spinal Muscular atrophy carrier testing and newborn screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]



Carrier testing[1], [2], [3] - Carrier testing helps to identify parents of SMA patients, who are carrier of the mutated genes. This can help to predict the future pregnancies in the parents.


  • PCR-based dosage assay – Detect Carrier parents of patients with homozygous deletions or compound heterozygosity.
  • Sequencing of the SMN gene - Detect point mutations.


New Born screening[3] may help to identify pre-symptomatic individuals and institution of early treatment (once it becomes available). This can prevent the occurrence of severe disease forms in future.


References

  1. McAndrew PE, Parsons DW, Simard LR, Rochette C, Ray PN, Mendell JR; et al. (1997). "Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number". Am J Hum Genet. 60 (6): 1411–22. doi:10.1086/515465. PMC 1716150. PMID 9199562.
  2. Eggermann T, Zerres K, Anhuf D, Kotzot D, Fauth C, Rudnik-Schöneborn S (2005). "Somatic mosaicism for a heterozygous deletion of the survival motor neuron (SMN1) gene". Eur J Hum Genet. 13 (3): 309–13. doi:10.1038/sj.ejhg.5201268. PMID 15586177.
  3. 3.0 3.1 Prior TW (2007). "Spinal muscular atrophy diagnostics". J Child Neurol. 22 (8): 952–6. doi:10.1177/0883073807305668. PMID 17761649.

External links

  • Template:NINDS
  • SMA Support
  • Spinal Muscular Atrophy - Fight SMA - An international nonprofit dedicated to finding a treatment or cure for spinal muscular atrophy. Visit Fight SMA's website and also the Spinal Muscular Atrophy Blog for the latest news and research information about the leading genetic killer of children under two.
  • Families of Spinal Muscular Atrophy - An international nonprofit dedicated to advancing research and supporting individuals and families with sma. FSMA has a web site with news, information and message boards for individuals to post questions. FSMA is one of the largest US private funders of SMA research and has more than 30 chapters worldwide.FSMA
  • SMA Trust - a UK registered charity working to fund medical research into Spinal Muscular Atrophy
  • Jennifer Trust for Spinal Muscular Atrophy - A national charity in the UK dedicated both to supporting people affected by SMA, and investing in essential research into causes, treatments and eventually a cure for the condition

Template:Diseases of the nervous system

da:Spinal muskulær atrofi de:Spinale Muskelatrophie el:Νωτιαία μυϊκή ατροφία nl:Spinale Musculaire Atrofieën fi:Spinaaliset lihasatrofiat sv:Spinal muskelatrofi


Template:WikiDoc Sources